DALLAS, Oct. 22, 2020 /PRNewswire/ -- Lantern
Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical
company using its proprietary RADR® artificial intelligence
("A.I.") platform to improve drug discovery and development, and
identify patients who will benefit from its portfolio of targeted
oncology therapeutics, announced today that it will host a
conference call and live webcast on Thursday, October 29, 2020 at 4:00 p.m. ET to discuss financial and operating
results for the third quarter ended September 30, 2020.
The call will be led by Panna
Sharma, President and Chief Executive Officer. He will be
joined on the call by other members of the management team.
Interested participants and investors may access the conference
call via teleconference or online.
Conference Call & Webcast
Details
Toll-free Domestic & Canada: 866.342.8588 conference ID:
55977
International: 203.518.9865 – conference ID
55977
US and Canada callers one
touch dial: +1.866.342.8588,,55977#
Live audio-only webcast and related presentation materials will
also be accessible at:
https://www.webcaster4.com/Webcast/Page/2460/38336. Web
participants should register 15 minutes prior to the start of the
call. The webcast will be archived on the Lantern Pharma website
for 45 days.
Replay Details
A replay of the conference call will be available through
November 29, 2020.
Replay Number: 1.800.925.9932 – passcode: 55977
About Lantern Pharma
Lantern Pharma (LTRN) is a clinical-stage biopharmaceutical
company innovating the repurposing, revitalization and development
of precision therapeutics in oncology. We leverage advances in
machine learning, genomics, and artificial intelligence by using a
proprietary A.I. platform to discover biomarker signatures that
help identify patients more likely to respond to our pipeline of
cancer therapeutics. Lantern's focus is to improve the outcome for
patients by leveraging our technology to uncover, rescue and
develop abandoned or failed drugs. Our current pipeline of three
drugs, with two programs in clinical stages and two in preclinical,
focuses on cancers that have unique and unmet clinical needs with a
clearly defined patient population. We believe that the use of
machine learning, genomics and computational methods can help
accelerate the revitalization, refocusing and development of small
molecule-based therapies. By targeting drugs to patients whose
genomic profile identifies them as having the highest probability
of benefiting from the drug, this approach represents the potential
to deliver best-in-class outcomes. Our team seeks out experienced
industry partners, world-class scientific advisors, and innovative
clinical-regulatory approaches to assist in delivering cancer
therapies to patients as quickly and efficiently as possible. For
more information, please visit the company's website at
www.lanternpharma.com or follow the company on Twitter
@lanternpharma.
Contact:
Marek
Ciszewski, JD
Director, Investor Relations
628-777-3167
investor@lanternpharma.com
Forward-looking Statements
This press release contains forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. These forward-looking statements include, among other
things, statements relating to: future events or our future
financial performance; the potential advantages of our
RADR® platform in identifying drug candidates and
patient populations that are likely to respond to a drug candidate;
our strategic plans to advance the development of our drug
candidates; estimates regarding the development timing for our drug
candidates; our strategic plans to expand the number of data points
that our RADR® platform can access and analyze; our
research and development efforts of our internal drug discovery
programs and the utilization of our RADR® platform to
streamline the drug development process; our intention to leverage
artificial intelligence, machine learning and genomic data to
streamline and transform the pace, risk and cost of oncology drug
discovery and development and to identify patient populations that
would likely respond to a drug candidate; and our plans to discover
and develop drug candidates and to maximize their commercial
potential by advancing such drug candidates ourselves or in
collaboration with others. There are a number of important factors
that could cause our actual results to differ materially from those
indicated by the forward-looking statements, such as the impact of
the COVID-19 pandemic, the results of our clinical trials, and the
impact of competition. Additional factors can be found in the Risk
Factors section in our final prospectus, dated June 10, 2020, for our initial public offering,
on file with the Securities and Exchange Commission. You may
access our June 10, 2020 final
prospectus under the investor SEC filings tab of our website at
www.lanternpharma.com or on the SEC's website at www.sec.gov.
Given these risks and uncertainties, we can give no assurances that
our forward-looking statements will prove to be accurate, or that
any other results or events projected or contemplated by our
forward-looking statements will in fact occur, and we caution
investors not to place undue reliance on these statements. All
forward-looking statements in this press release represent our
judgment as of the date hereof, and, except as otherwise required
by law, we disclaim any obligation to update any forward-looking
statements to conform the statement to actual results or changes in
our expectations.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/lantern-pharma-to-host-third-quarter-2020-operating-and-financial-results-conference-call-on-october-29-2020-at-400-pm-et-301157603.html
SOURCE Lantern Pharma